Skye Bioscience, Inc. Common Stock
Here’s whether Skye Bioscience, Inc. Common Stock (SKYE) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bearish.
Concerns: trading below the 200-day MA (long-term downtrend); below the 50-day MA (medium-term momentum negative); 50-day MA is falling (-6.97% over 10 days); weak 1-year return of -84.7%; 3-month momentum negative (-38.4%); rising volume on a downtrend (distribution, 2.31x avg). Currently 90.0% off its 52-week high. Score: -6/7.
SKYE is trading below its 200-day MA ($0.87) — a key warning sign the longer-term trend is under pressure. An RSI of 30.3 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of -84.7% compares to +20.4% for SPY (trailed the market by 105.0%). The current 90.0% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.